Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02652598
Other study ID # 805704
Secondary ID
Status Enrolling by invitation
Phase Phase 2
First received January 6, 2016
Last updated January 17, 2017
Start date November 2015

Study information

Verified date January 2017
Source Sheppard Pratt Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatment in the two subject groups (BI and NCD)


Description:

Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.

Clinical Instruments for patients:

- Question banks from large patient-reported outcome measure initiatives will be used and administered and used by computerized-adaptive tests (CATs). These include the TBI-QoL for patients with TBI and question banks from the patient-reported outcome measure information systems (PROMIS) and neurology quality of life measurement initiative (Neuro-QoL). Patients will answer questions related to their mobility, fatigue, pain interference, positive affect and well-being, depression, anxiety, anger and irritability, and emotional and behavioral dyscontrol.

- Clinical Global Impressions Scale

- Geriatric Depression Scale-15

- State-Trait Anxiety Inventory

- Hopkins Adult Reading Test

- Frontal Systems Behavior Scale

- Montreal Cognitive Assessment

- Trails A&B

- Modified Wisconsin Card Sorting Test

- NIH Toolbox

- Perceptual Comparison Test

- Brief Test of Attention

- Hopkins Verbal Learning Test

- Brief Visuospatial Memory Test

- Calibrated Ideational Fluency Assessment

- Profile of Mood States

- Digit Span

Clinical Instruments for Informants:

- Neuropsychiatry Inventory

- Apathy evaluation scale

- Overt aggression scale

- Frontal Systems Behavior Scale

Laboratory Measures:

- Blood sample for genotyping

- Blood sample for assessing COMT activity.

- Blood sample for a laboratory profile including CBC, CMP, TSH, Hepatitis Panel (B and C), and RPR

- A urine analysis, urine drug screen, and a urine pregnancy test

- In addition for NCD patients: a blood sample for tests including Serum Calcium, B12, ESR, and C-reactive protein


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility TBI and ABI Patients Inclusion Criteria

- Age 18-70

- Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury.

- Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation

- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI

- Proficient in the English language

- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol

- Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician.

- Stable medication dose and regimen for 2 months

NCD Patients Inclusion Criteria

- Age 60-75

- NCD diagnosed by a Sheppard Pratt physician, per DSM-5

- No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR.

- Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion)

- Proficient in the English language

- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD

- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol

- Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician.

- Stable medication dose and regimen for 2 months

Exclusion Criteria for All Patients:

- History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1

- Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe

- History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure

- Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg)

- History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic

- Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe

- Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, a-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor

- Known allergy or serious adverse reaction to tolcapone

- Participated in any investigational drug trial in the past 30 days.

- Pregnant or planning to become pregnant during the study period

- Breastfeeding or planning to breastfeed during the study period.

Other Exclusion Criteria for TBI Patients

• Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation

Study Design


Intervention

Drug:
Tolcapone


Locations

Country Name City State
United States Sheppard Pratt Health System Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Sheppard Pratt Health System Lieber Institute for Brain Development (LIBD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Clinical Global Impression Scale (CGI) to two weeks after medication administration Up to 2 weeks
Secondary Change from Baseline TBI-QoL to two weeks after medication administration Questions from the TBI-QoL battery, which consists of tests to assess items on domains of emotion, social activity, physical activity, and cognition Up to 2 weeks
Secondary Change from Baseline NIH Toolbox Cognition Battery to two weeks after medication administration A cognition battery developed by NIH, which consists of tests to assess Executive Function, Attention, Episodic Memory, Language, Processing Speed and Working Memory. Up to 2 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05542108 - Adding Motion to Contact: A New Model for Low-cost Family Centered Very-early Onset Intervention in Very Preterm-born Infants N/A
Completed NCT03400904 - Extubation Strategies in Neuro-Intensive Care Unit Patients and Associations With Outcome.
Completed NCT06073145 - Transcranial Doppler Using Wearable Ultrasound Patch
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Not yet recruiting NCT05833568 - Five-day 20-minute 10-Hz tACS in Patients With a Disorder of Consciousness N/A
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Completed NCT03162484 - Physical Activity and Chronic Acquired Brain Injury N/A
Not yet recruiting NCT02756585 - Computed Tomography Perfusion in Patients With Severe Head Injury N/A
Terminated NCT01430988 - Observational Study of the BrainScope® Ahead™ M-100 in UK Emergency Department Patients With Head Injury N/A
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A
Completed NCT00975338 - The LETS Study: A Longitudinal Evaluation of Transition Services
Completed NCT00878631 - Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Phase 2/Phase 3
Completed NCT03166722 - Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition N/A
Not yet recruiting NCT04478812 - Tbit System Precision and Correlation of Different Blood Samples N/A
Recruiting NCT05309005 - Virtual Reality and Social Cognition After Acquired Brain Injury
Recruiting NCT05443542 - VIrtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With ABI N/A
Completed NCT02702635 - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging N/A
Withdrawn NCT04247321 - Non-invasive Near-infrared Spectroscopy (NIRS) Versus Invasive Licox Intracranial Pressure N/A
Not yet recruiting NCT04386525 - Omega 3 and Ischemic Stroke; Fish Oil as an Option Phase 4